Sun Zhixiang 孙志祥

孙志祥,生于1967年,汉族,中国籍,复旦大学法学学士,复旦大学国际经济法学硕士,美国哈佛大学高级访问学者。从事法律咨询工作超过30年,在投融资、企业事务、证券交易等领域有丰富的经验。历任上海市对外经济律师事务所律师,新加坡姚海伦律师事务所中国法律顾问,上海市新闵律师事务所涉外金融部主任,现任上海市浦栋律师事务所高级合伙人。自2021年1月起,任MicroPort CardioFlow Medtech Corporation(于香港联交所上市,股票代码:HK02160)独立董事;自2023年5月起,任上海宝信软件股份有限公司(于上海证券交易所上市,股票代码:600845)独立董事;自2024年6月起,任上海外服控股集团股份有限公司(于上海证券交易所上市,股票代码:600662)独立董事。自2025年12月起担任公司独立董事。

English Translation 英文译文 · Organisation Names in Chinese 机构名称保留中文Sun Zhixiang, born in 1967, Han ethnicity, Chinese nationality, Bachelor of Laws from 复旦大学, Master of International Economic Law from 复旦大学, Senior Visiting Scholar at 美国哈佛大学. Over 30 years of experience in legal consulting, with extensive experience in investment and financing, corporate affairs, and securities trading. Held positions as a lawyer at 上海市对外经济律师事务所, legal counsel for 新加坡姚海伦律师事务所, Director of the International Finance Department at 上海市新闵律师事务所, and currently a Senior Partner at 上海市浦栋律师事务所. Since January 2021, Independent Director of MicroPort CardioFlow Medtech Corporation (listed on 联交所 in Hong Kong, stock code: HK02160); Since May 2023, Independent Director of 上海宝信软件股份有限公司 (Baosight) (listed on 上海证券交易所, stock code: 600845); Since June 2024, Independent Director of 上海外服控股集团股份有限公司 (Shanghai Foreign Service Holding Group) (listed on 上海证券交易所, stock code: 600662). Since December 2025, Independent Director of the company.